Since BHPI is not a competitive inhibitor of ERα (43) and targets ERα positive cancer cells irrespective of their dependence on E2 for proliferation, it is a promising preclinical drug candidate for the treatment of metastatic breast cancers expressing ERαY537S and ERαD538G. Here, ERAS is linked to breast carcinoma.